NGM-621 is a recombinant human IgG1/kappa monoclonal antibody targeting Complement C3, produced in CHO cells with an approximate molecular weight of 149.04 kDa. It is utilized in research to investigate complement pathway inhibition in models of age-related macular degeneration (AMD) and other complement-mediated diseases, both in vitro and in vivo.
Clonality:
Monoclonal
Concentration:
5.39 mg/mL
Molecular Weight:
144.78 kDa
Purity:
98.10% (May vary between batches)
Target:
Complement System
* VAT and and shipping costs not included. Errors and price changes excepted